MarketPulse

DME

2 articles
GlobeNewswire Inc.GlobeNewswire Inc.··Oculis Holding Ag

Oculis Eyes DME Market With First Eye Drop Therapy as ARVO Data Show Unmet Need

Oculis' DME AWARE study confirms expert demand for non-invasive treatment; OCS-01 eye drops target June 2026 Phase 3 results as potential first-in-class DME therapy.
OCSOCSAWdiabetic macular edemanon-invasive treatment
GlobeNewswire Inc.GlobeNewswire Inc.··Oculis Holding Ag

Oculis Eyes DME Market Opportunity as Study Reveals 60% Patient Non-Treatment Rate

Oculis-backed research reveals significant unmet needs in diabetic macular edema treatment, with 60% of patients remaining untreated due to invasive therapies.
OCSOCSAWdiabetic macular edemanon-invasive treatment